Perrigo Co. (PRGO) EVP Judy L. Brown Sells 2,097 Shares
Perrigo Co. (NYSE:PRGO) EVP Judy L. Brown sold 2,097 shares of the business’s stock in a transaction on Friday, November 25th. The stock was sold at an average price of $89.44, for a total value of $187,555.68. Following the completion of the sale, the executive vice president now directly owns 10,007 shares in the company, valued at approximately $895,026.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Perrigo Co. (NYSE:PRGO) opened at 88.19 on Tuesday. Perrigo Co. has a 52 week low of $79.72 and a 52 week high of $152.36. The stock’s market cap is $12.64 billion. The firm has a 50-day moving average price of $87.46 and a 200-day moving average price of $91.83.
Perrigo (NYSE:PRGO) last posted its quarterly earnings results on Thursday, November 10th. The company reported $1.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.58 by $0.07. The company had revenue of $1.40 billion for the quarter, compared to the consensus estimate of $1.28 billion. Perrigo had a positive return on equity of 10.78% and a negative net margin of 26.62%. The firm’s quarterly revenue was up .8% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.76 EPS. On average, equities research analysts predict that Perrigo Co. will post $6.98 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 13th. Stockholders of record on Friday, November 25th will be paid a $0.145 dividend. This represents a $0.58 dividend on an annualized basis and a dividend yield of 0.66%. The ex-dividend date of this dividend is Tuesday, November 22nd. Perrigo’s dividend payout ratio (DPR) is currently -5.53%.
A number of analysts have recently commented on the company. Argus reissued a “hold” rating on shares of Perrigo in a research note on Tuesday, September 27th. Vetr downgraded Perrigo from a “buy” rating to a “hold” rating and set a $98.60 price objective on the stock. in a research note on Tuesday, August 9th. Deutsche Bank AG reissued a “buy” rating and issued a $105.00 price objective on shares of Perrigo in a research note on Tuesday, September 13th. RBC Capital Markets reissued a “sector perform” rating and issued a $92.00 price objective on shares of Perrigo in a research note on Tuesday, September 20th. Finally, Guggenheim set a $125.00 target price on Perrigo and gave the stock a “buy” rating in a report on Thursday, September 15th. One research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and four have assigned a buy rating to the company. Perrigo presently has a consensus rating of “Hold” and an average price target of $109.45.
Several hedge funds and other institutional investors have recently bought and sold shares of PRGO. Trust Co increased its position in Perrigo by 0.6% in the first quarter. Trust Co now owns 2,610 shares of the company’s stock worth $334,000 after buying an additional 15 shares during the period. Taylor Frigon Capital Management LLC increased its position in Perrigo by 0.3% in the second quarter. Taylor Frigon Capital Management LLC now owns 9,077 shares of the company’s stock worth $823,000 after buying an additional 29 shares during the period. Cadence Capital Management LLC increased its position in Perrigo by 1.2% in the second quarter. Cadence Capital Management LLC now owns 2,733 shares of the company’s stock worth $248,000 after buying an additional 33 shares during the period. Sumitomo Mitsui Asset Management Company LTD increased its position in Perrigo by 0.4% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 11,026 shares of the company’s stock worth $999,000 after buying an additional 44 shares during the period. Finally, Cambridge Investment Research Advisors Inc. increased its position in Perrigo by 2.3% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 3,911 shares of the company’s stock worth $355,000 after buying an additional 89 shares during the period. 69.38% of the stock is currently owned by institutional investors.
Perrigo Company Profile
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Stock Ratings for Perrigo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo Co. and related stocks with our FREE daily email newsletter.